Patents by Inventor Masanori Saitou

Masanori Saitou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOPYRAZOLE DERIVATIVE
    Publication number: 20220185815
    Abstract: The present invention provides a low molecular compound that inhibits phosphatidylserine synthase 1 or a pharmaceutically acceptable salt thereof, a pharmaceutical containing thereof, and a therapeutic agent for cancer having a suppressed function of phosphatidylserine synthase 2. The compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein R1, ring Q1, ring Q2, and W are as defined in the specification.
    Type: Application
    Filed: March 5, 2020
    Publication date: June 16, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hidenori NAMIKI, Masanori SAITOU, Satoshi MATSUI, Yoshihiro SHIBATA, Yoshito KAWAMOTO, Rie ICHIKAWA, Yohei YOSHIHAMA, Akiko OTSUKA
  • Morpholinopurine derivatives
    Patent number: 8309546
    Abstract: There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: November 13, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kiyoshi Nakayama, Kazuyuki Sugita, Masaki Setoguchi, Yuichi Tominaga, Masanori Saitou, Takashi Odagiri
  • MORPHOLINOPURINE DERIVATIVES
    Publication number: 20120071476
    Abstract: There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 22, 2012
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kiyoshi Nakayama, Kazuyuki Sugita, Masaki Setoguchi, Yuichi Tominaga, Masanori Saitou, Takashi Odagiri
  • Morpholinopurine derivatives
    Patent number: 8097622
    Abstract: There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: January 17, 2012
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kiyoshi Nakayama, Kazuyuki Sugita, Masaki Setoguchi, Yuichi Tominaga, Masanori Saitou, Takashi Odagiri
  • MORPHOLINOPURINE DERIVATIVES
    Publication number: 20100130492
    Abstract: There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.
    Type: Application
    Filed: October 14, 2009
    Publication date: May 27, 2010
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kiyoshi Nakayama, Kazuyuki Sugita, Masaki Setoguchi, Yuichi Tominaga, Masanori Saitou, Takashi Odagiri